Safety and Effectiveness Evaluation of a Public Smoking Cessation Policy
This is an evaluation of the BC Ministry of Healths smoking cessation policy. The evaluation will consist of 4 analyses:
1. What is the comparative effectiveness of Champix, Zyban, Thrive, and Habitrol therapy for smoking cessation in a population based publicly funded reimbursement program?
Hypothesis: No difference in smoking cessation effectiveness.
2. What is the comparative safety of Champix, Zyban, Thrive, and Habitrol therapy for smoking cessation in a population based publicly funded reimbursement program.
Hypothesis: No difference in safety, in terms of mortality, suicidality, and total emergency hospital admissions.
3. How do the direct system health costs compare between smoking cessation products offered under BC's population based tobacco treatment program.
Hypothesis: Any difference in cost is comparable to the difference cost for each product.
4. What effect did the Smoking Cessation Program have on utilization rates of use of the four smoking cessation products?
Hypothesis: The Smoking Cessation Program increased the utilization of smoking cessation products.